Probiotics to Treat "Inflammatory Depression"

Inclusion criteria

• Age, 18-85
• Depressive episode according to the DSM-V
• MADRS-M score >18
• All subjects will be stable on an antidepressant medication or in Cognitive Behavioural Therapy (CBT) for >4 weeks
• Subjects will be willing not to significantly alter their diet during the period of the study
• A hs-CRP value ≥1mg/L and BMI >25

Exclusion criteria

• Serious or unstable medical illness that in the investigator's opinion could compromise response to treatment or interpretation of study results.
• Known or suspected allergy to the study compounds.
• Ongoing infection.
• A diagnosis of psychotic disorder, bipolar disorder, personality disorder mental retardation, dementia, or individual whom, due to other causes, lack the ability to make an informed decision.
• Ongoing ECT.
• Patients who, in the investigator's judgment, pose a current, serious suicidal.
• A diagnosis for any Substance Use Disorder (except nicotine or caffeine) in the 3 months prior to the screening visit.
• Any medications (within 1 week of baseline or during the trial) that might confound the biomarker findings, including: Regular ingestion of NSAIDs or COX-2 inhibitors, or any use of oral steroids, immunosuppressants, interferon, chemotherapy (Patients will be instructed not to take an NSAID, COX-2 inhibitor or Aspirin in the 24 hours prior to a biomarker assessment visit).
• Antibiotic treatment/consumption within four (4) weeks before baseline visit.
• Patients who have taken foods or supplements with Probiotics later than two (2) weeks before baseline visit.
• Active participation in other clinical studies with ongoing study visits.
• Pregnancy.